{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5%25+albumin", "query": { "intervention": "5% albumin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 262, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=5%25+albumin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T00:51:44.632Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07423078", "title": "Window of Opportunity in Preserving Laryngeal Function Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)", "Locally Advanced Laryngeal Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma" ], "interventions": [ { "name": "Toripalimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Matthew Spector", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2026-04-06", "completion_date": "2031-04-30", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07423078" }, { "nct_id": "NCT04492475", "title": "Adaptive COVID-19 Treatment Trial 3 (ACTT-3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 969, "start_date": "2020-08-05", "completion_date": "2020-12-21", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04492475" }, { "nct_id": "NCT02662634", "title": "A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "AGS-003-LNG", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "Alimta", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Taxol", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "GU Research Network, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 0, "start_date": "2016-03", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2022-03-18", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02662634" }, { "nct_id": "NCT06445062", "title": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "CRC", "Pancreatic Ductal Adenocarcinoma", "PDAC", "Gastrointestinal Cancer", "Metastatic Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RMC-6236", "type": "DRUG" }, { "name": "mFOLFOX6 regimen", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "mFOLFIRINOX regimen", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "RMC-9805", "type": "DRUG" }, { "name": "FOLFIRI regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1130, "start_date": "2024-05-24", "completion_date": "2030-03-30", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 32, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06445062" }, { "nct_id": "NCT03563170", "title": "QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma Non-resectable", "Hepatocellular Carcinoma Recurrent" ], "interventions": [ { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "haNK for infusion", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" }, { "name": "Aldoxorubicin hydrochloride", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "N-803", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-05-25", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2021-03-18", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563170" }, { "nct_id": "NCT00503906", "title": "Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Avastin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Miami", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 30, "start_date": "2007-06", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-05-12", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00503906" }, { "nct_id": "NCT05281471", "title": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "High-grade Serous Ovarian Cancer", "Endometrioid Ovarian Cancer", "Ovarian Clear Cell Carcinoma" ], "interventions": [ { "name": "olvimulogene nanivacirepvec", "type": "BIOLOGICAL" }, { "name": "Platinum chemotherapy: carboplatin (preferred) or cisplatin", "type": "DRUG" }, { "name": "Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Bevacizumab (or biosimilar)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genelux Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 186, "start_date": "2022-08-31", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 33, "location_summary": "Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05281471" }, { "nct_id": "NCT01376700", "title": "Early Prophylaxis Immunologic Challenge (EPIC) Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hemophilia A" ], "interventions": [ { "name": "Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "1 Year", "sex": "MALE", "summary": "Up to 1 Year · Male only" }, "enrollment_count": 22, "start_date": "2011-08-26", "completion_date": "2012-11-16", "has_results": true, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 2, "location_summary": "Indianapolis, Indiana • New Brunswick, New Jersey", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01376700" }, { "nct_id": "NCT01744353", "title": "BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Dose level 1", "type": "DRUG" }, { "name": "Dose level 2/MTD", "type": "DRUG" }, { "name": "Dose level 3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2012-11", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 3, "location_summary": "Pawtucket, Rhode Island • Providence, Rhode Island", "locations": [ { "city": "Pawtucket", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01744353" }, { "nct_id": "NCT02283372", "title": "Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Intensity modulated radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-01-21", "completion_date": "2019-04-18", "has_results": false, "last_update_posted_date": "2019-06-19", "last_synced_at": "2026-09-28T00:51:44.632Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02283372" } ] }